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Background: There is increasing evidence of systemic inflammation in patients with
chronic obstructive pulmonary disease (COPD), but there is very little information on the
development of systemic inflammation in smokers without severe airway symptoms. In this
longitudinal study, we examined whether smokers with mild or no airway symptoms
develop signs of systemic inflammation by assessing inflammatory markers in blood over a
6-year period.
Methods: Forty smokers and 28 male never-smokers were investigated in 1995 (year 0)
and 6 years later (year 6). At year 6, 11 smokers had stopped smoking (quitters); these
subjects were analysed as a separate group. At year 0 and 6, we measured serum levels of
myeloperoxidase (MPO), lysozyme and human neutrophil lipocalin (HNL), regarded as
markers of activity in neutrophils plus monocyte-lineage cells, monocyte-lineage cells only
and neutrophils only.
Results: All systemic markers of inflammation (MPO, HNL and lysozyme) were significantly
higher in smokers than in never smokers at year 6. For MPO alone, smokers only displayed a
unique pattern compared with the other groups; the concentration of MPO in blood
increased among smokers during the 6-year period, and this increase was statistically
significant compared with that observed in never-smokers. Even though quitters did not
display any clear change in MPO, we observed a statistically significant negative
correlation between the change in blood MPO and the duration of smoking cessation in
this group. For HNL and lysozyme, the changes over time were similar in smokers and
never-smokers, with no statistically significant difference compared with quitters.Elsevier Ltd. All rights reserved.
Medicine and Allergology, Sahlgrenska University Hospital, Bruna stra˚ket 11, S-413 45 Go¨teborg,
6 31 82 49 04.
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Systemic inflammation in smokers 889Conclusion: This study provides evidence that male smokers without severe airway
symptoms develop an increasing systemic inflammation during a 6-year period. The study
forwards both direct and indirect evidence that MPO may be an early marker of this
systemic inflammation. However, our study also forwards indirect evidence that ongoing
tobacco smoking may ‘‘drive’’ the level of systemic HNL and lysozyme. The origin of the
increased MPO and its value as an easily measured predictor for future COPD deserves to be
further evaluated.
& 2006 Elsevier Ltd. All rights reserved.Introduction
It is now widely accepted that chronic obstructive pulmon-
ary disease (COPD) is characterised by local tissue destruc-
tion in the lung.1 There are now also many studies providing
evidence that these destructive changes are causally related
to a local inflammatory process involving leukocytes such as
neutrophils and monocyte-lineage cells including macro-
phages.2–6
More recently, clinical studies have demonstrated signs of
systemic inflammation in patients with severe COPD.7,8
Interestingly, in COPD patients, certain markers of systemic
inflammation may be linked to weight loss and waste of
skeletal muscle.9 Moreover, the change over time in other
markers of systemic inflammation may reflect the severity of
COPD as well.10 Hypothetically, systemic inflammation may
constitute a mechanistic link between COPD and other
tobacco-related diseases, including cardiovascular diseases
11 and degeneration of the maculae, even though the
mechanistic understanding of such events remain poor.12
It is known that tobacco smokers display a higher
concentration of blood leukocytes than do non-smokers.13,14
This phenomenon is not restricted to patients with COPD; it
is also found in smokers with mild or no airway symptoms.8
Several studies have revealed a correlation between the
leukocyte count in the peripheral blood and the status of
current smoking.15,16 Interestingly, the increased concen-
tration of blood leukocytes tends to be normalised after
smoking cessation, indicating that this increase in leuko-
cytes is a reversible phenomenon.16,17 For blood neutro-
phils, there is a relatively rapid normalisation within the
first year after smoking cessation, whereas the normal-
isation of lymphocytes and monocytes may take up to 5
years.15 One study on blood neutrophils from patients with
COPD indicates an enhanced cellular responsiveness to
stimulation with the pro-inflammatory cytokine tumor
necrosis factor (TNF)-a as well as an increased expression
of surface adhesion molecules, thus suggesting an increased
readiness for these particular leukocytes to enter the
inflamed target organ (i.e. the lung), through extravasation,
once a local pathogenic stimulus is acting.18 The mechan-
istic role of monocytes in COPD is not fully understood but
an increase of these cells in blood has been associated with
an increased risk of cardiovascular heart disease and
atherosclerosis19 and the incidence of these clinical condi-
tions is clearly augmented in patients with COPD.20
We have previously published a transectional cohort study
on inflammatory markers in blood and lung function in male
smokers, with mild or no airway symptoms, compared with
never-smokers.21 In that study, the group of smokers hadsignificantly higher levels of myeloperoxidase (MPO) and
human neutrophil lipocalin (HNL) than the group of never-
smokers at the only one time point of investigation.
Tentatively, these findings may reflect an increased systemic
activity among circulating monocytes and/or neutrophils.
However, it is not known how these markers of systemic
inflammation change over a longer period of time in smokers
with mild or no airway symptoms.
In the current study, we aimed to characterise signs of
systemic inflammation over a longer period of time in
smokers without severe airway symptoms at baseline.
Analysing serum from peripheral blood samples harvested
at baseline and 6 years later, we targeted MPO as a
combined marker of activity in neutrophils and cells of the
monocyte lineage,22 lysozyme as a marker of activity in cells
of the monocyte lineage 23 and finally HNL as a specific
marker of neutrophil activity.24Material and methods
Design
Blood samples were harvested in a male cohort at two time
points, 6 years apart, and where stored as serum at 701 for
later analysis of soluble inflammatory markers. In both
cases, the analyses of soluble inflammatory markers in
serum where conducted within 2 years. In doing so, we
hoped to avoid introducing ageing of samples as a
confounding factor for any difference between year 0 and 6.Subjects
The subjects were recruited from the WHO population
study’’Men born 1933 in Go¨teborg’’ 25 a randomised half of
all men born in 1933 and resident in Gothenburg in 1983
(n ¼ 1016). From the original cohort, 92 men, 58 smokers
and 34 never-smokers were recruited to further investiga-
tions concerning respiratory symptoms and inflammatory
markers in 1994 (Year 0).21 All subjects regarded themselves
as healthy and had no previous medical contact due to
respiratory disease. However, as indicated by the local study
questionnaire about 40% of the smokers year 0 reported
‘‘ever having had problems with their breathing’’ or with
mucus compared to 26%, respectively, 11% of the never
smokers (Table 2). The baseline (Year 0) values of the
included data sets on MPO, lysozyme and HNL have been
utilised in one previous publication.21 At year 0, all subjects
underwent lung function tests including spirometry and test
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samples.
In 2000, the 92 subjects from year 0 were asked to
participate in a follow-up study (for sampling at year 6).
Sixty-eight subjects came to the follow-up investigation at
year 6; 29 current smokers, 28 never-smokers and 11
‘‘quitters’’, who had quit smoking since Year 0 according
to self-reported data in the local questionnaire. The follow-
up examinations took place in 2000 and 2001, when the
subjects were 67 to 68 years old. The median follow-up time
was somewhat more than 6 years (median: 75 months;
range: 60–83 months).
Twenty-four recruited subjects did not complete the
follow-up examination at year 6. Seven of these subjects
were never-smokers and 17 were smokers. Seven subjects
had died since year 0; all were smokers. Causes of death
were cancer (n ¼ 4), myocardial infarction (n ¼ 1), bronch-
opneumonia (n ¼ 1) and suicide (n ¼ 1). Patients presenting
airway symptoms at Year 6 (but not at Year 0) remained and
were included in our study. Both at Year 0 and 6, the
examination was postponed for 4 weeks in case of infection.
Ethics
The study was approved by the local Ethics Committee at
Sahlgrenska University Hospital, Go¨teborg, Sweden (Diary
No 425/95 and Diary No 578/9). Informed consent was
obtained from all patients. All research was conducted in
accordance with the Helsinki Declaration.26
Questionnaire
All subjects answered a questionnaire. The questionnaire
was a modified version of the European Community
Respiratory Health Survey.27 It was divided into three
principal parts. The first section contained items on airway
symptoms, including wheeze, shortness of breath, cough,
sputum production and one unspecific question : ‘‘Do you
ever have trouble with your breathing?’’. The second section
contained items on smoking habits. In the last section, the
subjects were asked about other diseases and concomitant
medication. The subjects answered the questionnaire prior
to undergoing lung function tests.
Lung function tests
Lung function was tested using spirometry and diffusion
capacity test at Year 0 and 6 respectively (Table 3). Forced
expiratory volume in 1 s (FEV1) and vital capacity (VC) were
obtained on a regularly calibrated spirometer. Carbon
monoxide transfer (DLCO) was assessed by the single breath
method (SensorMedics 2200, SensorMedics Co, Bilthoven,
the Netherlands). We used the European Respiratory Society
reference values 28 for spirometry and the reference values
according to Salorinne29 for (DLCO).
Inflammatory markers in peripheral blood
Human neutrophil lipocalin (HNL) was determined in thawed
serum using a double-antibody radioimmunoassay (RIA).30Briefly, HNL in standard or sample was allowed to bind to an
anti-HNL mouse monoclonal antibody (mab) coupled to
ImmunoCAP (Pharmacia & Upjohn, Diagnostic AB, Uppsala
Sweden). After washing, beta-galatosidase labelled anti-
HNL mab was added and allowed to bind to the HNL. After a
final wash, the amount of HNL was determined by
fluorescence after adding 4-methylumbelliferyl-beta-D-ga-
lactoside as enzyme substrate. HNL, purified from neutro-
phil granulocytes, was used as standard (20–600 mg/L). The
intra-assay and inter-assay coefficients of variation were
less than 10% and the lower detection limit was 3mg/L.
MPO was determined in serum with a double antibody
radioimmunoassay. MPO in the sample competed with a
fixed amount of I125-labelled MPO for the binding sites of
specific anti-MPO antibodies; antibodies that were raised in
rabbit (Pharmacia & Upjohn, Diagnostic AB, Uppsala
Sweden). Bound and free MPO molecules were separated
by adding a second anti-rabbit IgG antibody coupled to
Sepharose; a procedure followed by centrifugation and
decanting. Finally, the radioactivity in the pellet was
measured using a gamma counter (CliniGamma 1272, LKB,
Bromma, Sweden). Human MPO was used as standard
(8–1060mg/L). The intra-assay and inter-assay coefficient
of variation were less than 10% and the lower detection limit
was less than 8mg/L.
Lysozyme was titrated in serum by incubating standard
solution or samples with Sephadex-bound anti-lysozyme
during 2 h before an addition of I125-labelled lysozyme.31 The
incubation continued during another 20 h with rotation end
over end. After washing four times, the radioactivity of the
pellet was determined in a well-type scintillation counter .
Lysozyme purified from human blood was used as a standard
(3–900 mg/L). The intra-assay and interassay coefficients of
variation were less than 10%, and the lower detection limit
was 3 mg/L.
The analyses of HNL and lysozyme were conducted at the
Department of Medical Sciences, Clinical Chemistry, Uni-
versity of Uppsala. Differential counts from peripheral blood
were not available for this study.
Statistical methods
The Mann–Whitney U-test was used for the comparison of
inflammatory markers between smokers and never-smokers
and quitters. All data are presented as mean values with SD
or SEM, as appropriate. The number of human subjects is
referred to as n.
Results
Subjects
At Year 6, the subjects were retrospectively re-organised
into the following groups: smokers (n ¼ 29), smokers who
had quit smoking during the 6-year period (‘‘quitters’’;
n ¼ 11) and never-smokers (n ¼ 28). Table 1 shows the
cigarette consumption, height and BMI for these groups.
There was a small difference in cigarette consumption (i.e.
pack-years) for smokers and quitters at baseline (Year 0) but
there was no substantial difference in Body Mass Index (BMI)
between these two groups at baseline. We found no major
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Table 1 Subject characteristics.
Smokers (n ¼ 29) Quitters (n ¼ 11) Never smokers (n ¼ 28)
Year 0 Year 6 Year 0 Year 6 Year 0 Year 6
61.5(0.5) 67.5(0.5) 61.5(0.5) 67.5(0.5) 61.5(0.5) 67.5(0.5)
Height (cm) 175(4) 174(6) 175(7) 175(7) 177(7) 177(7)
BMI 26(4) 26(4) 26(2) 28(2) 27(2) 27(3)
Packyears 36(14) 40(15) 28(14) 29(14) — —
Data presented as mean (SD). ‘‘Quitters’’ refer to smoking subjects who quit smoking during the observation period.
Table 2 Symptoms according to study questionnaire.
Smokers (n ¼ 29) Quitters (n ¼ 11) Never smokers (n ¼ 28)
Year 0 Year 6 Year 0 Year 6 Year 0 Year 6
Ever had breathing problems (%) 39 41 36 46 26 18
Wheeze (%) 54 48 36 27 7 14
Sputum (%) 41 38 46 18 11 7
Data presented as % of symptoms in each group (smokers, quitters, never-smokers). ‘‘Quitters’’ refer to smoking subjects who quit
smoking during the observation period.
Table 3 Lung function tests.
Smokers (n ¼ 29) Quitters (n ¼ 11) Never-smokers (n ¼ 28)
Year 0 Year 6 Year 0 Year 6 Year 0 Year 6
VC (% pred) 89(14) 98(18) 86(9) 93(12) 92(12) 102(14)
FEV1 (% pred) 95(18) 85(21) 97(8) 90(12) 106(14) 103(14)
DLCO (% pred) 83(17) 76(19) 83(12) 78(15) 96(14) 97(15)
Data presented as mean (SD). ‘‘Quitters’’ refer to smoking subjects who quit smoking during the observation period.
Systemic inflammation in smokers 891change in BMI over time in smokers or never smokers
whereas ‘‘quitters’’ did display a slight increase in BMI. As
shown in Table 2, smokers did not display any pronounced
increase in reported symptoms during the 6-year period.
Interestingly, ‘‘quitters’’ tended to report markedly less
sputum symptoms at Year 6.Lung function
We found no substantial changes in either VC, FEV1 or DLCO
during the 6-year period (Table 3). There were no indica-
tions of a poorer lung function among subjects that did not
complete the study compared with those who did (data not
shown).Inflammatory markers in blood
At Year 6, all systemic markers of inflammation (MPO,
lysozyme and HNL) were significantly higher in smokers than
in never-smokers (Fig. 1a–c).We also analysed the change (Year 6Year 0) in the
concentrations of MPO, lysozyme and HNL, respectively. This
analysis revealed that MPO alone displayed a pattern of
change that was unique for smokers only, compared with the
other groups. Thus, the increase in MPO was significantly
more pronounced in smokers compared with never-smokers,
but not compared with quitters, who displayed an inter-
mediate degree of change (Table 4). For HNL and lysozyme,
these changes over time were similar in smokers and never
smokers, while the corresponding changes in quitters tended
to be smaller, with no statistically significant differences
between the groups.Relationship between inflammatory markers in
blood and duration of smoking cessation
A statistically significant and relatively strong negative
correlation was found for the duration of smoking cessation,
on one hand, and the change (delta value) in MPO, lysozyme
and HNL respectively, on the other hand (Fig. 2).
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Figure 1 Concentration of the inflammatory markers myelo-
peroxidase (MPO, A), lysozyme (B) and human neutrophilic
lipocalin (HNL, C) in blood over a 6-year period in male smokers
(dashed lines), never-smokers (plain lines) and smokers who
quit smoking during the observation period (quitters, dotted
lines). The change in each inflammatory marker is presented in
Table 4 as are the analytical statistics. All data in the figures are
presented as mean values 7SEM bars. n ¼ 11229. * ¼ Po 0.05
for smokers vs. never smokers and quitters respectively.
Table 4 Change for inflammatory markers in blood
during a 6-year period.
Smokers
(n ¼ 29)
Quitters
(n ¼ 11)
Never-smokers
(n ¼ 28)
MPO (mg/L) 131(33) 70(39)ns 44(23)*
LYS (mg/L) 225(68) 28(102)ns 206(36)ns
HNL (mg/L) 31(5) 7(9)ns 34(4)ns
Data presented as mean (SEM). (*P ¼ 0:04 compared with
smokers, ns-p40.4 compared with smokers.)
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Figure 2 Change in (delta) MPO, (A) HNL, (B) and lysozyme (C)
in blood from quitters (see Fig. 1) versus duration of smoking
cessation during a 6-year observation period. n ¼ 9. (A)
P ¼ 0:03, Rs ¼ 0.77; (B) P ¼ 0:01, Rs ¼ 0.93; and (C) P ¼ 0:05,
Rs ¼ 0.70.
K. Andelid et al.892Relationship between inflammatory markers in
blood and lung function
We found no evident correlation between, on one hand,
the delta values for FEV1, and diffusion capacity, and the
delta values for MPO, lysozyme and HNL, on the other hand,
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shown).
Relationship between inflammatory markers in
blood and BMI
We did not notice any clear evidence of a correlation
between BMI, on one hand, and the delta values for MPO,
lysozyme and HNL, on the other hand, in either smokers,
never smokers or quitters (data not shown).
Discussion
This 6-year study on blood samples from male smokers, with
mild or no airway symptoms at baseline, indicates that
among the inflammatory markers MPO, lysozyme and HNL,
MPO alone displays an increase that is unique for subjects
who continue to smoke (smokers) throughout the observa-
tion period. In addition to this direct evidence for a systemic
inflammation driven by tobacco smoking, our study suggests
that the absolute levels of MPO, lysozyme and HNL are all
higher in smokers than in never-smokers, as indicated at
Year 6 in this study, in support of previously published data
from Year 0 using the same material.21 Moreover, the current
study forwards indirect evidence of systemic inflammation
driven by tobacco smoking by demonstrating that quitters
display a statistically significant negative correlation be-
tween the level of MPO, lysozyme and HNL, on one hand,
and duration of cessation, on the other hand.
From a hypothetical point-of-view, our direct evidence
for an increase in systemic MPO driven by tobacco smoking is
compatible with either neutrophils or monocyte-lineage
cells being important cells for generating systemic inflam-
mation in male smokers, even though the current study does
not reveal whether these cells are active locally or
systemically. It has been claimed that the major part of
MPO in blood originates from blood neutrophils and, if true,
then our current findings on MPO clearly argue for
neutrophils being involved in systemic inflammation caused
by tobacco smoking.32 On the other hand, an involvement of
monocyte-lineage cells is compatible with a study showing
that, if harvested from patients with COPD and subsequently
stimulated in vitro, monocyte-lineage cells are capable of
producing more TNF-a, than those obtained from healthy
controls subjects.33 In the referred study, this was particu-
larly evident in patients with COPD and low body weight,
suggesting that excessive activity in blood monocytes is
pathogenically associated with weight loss in COPD. It is
noteworthy that a pathogenic role of activated monocyte-
lineage cells in blood is also compatible with, although not
proving, a pathogenic role of alveolar macrophages, the
latter being supported by several recent studies on clinical
materials.34,35
In further support of an active role of MPO in systemic
inflammation caused by tobacco smoking, it has been shown
that smokers with COPD are at increased risk of cardiovas-
cular diseases and, in patients with coronary artery disease,
MPO levels in blood are higher than in controls.32 Moreover,
in patients with arteriosclerosis, there is an association
between MPO gene promoter polymorphism and the severity
of the disease in the arterial wall already in middle age.36Finally, a high monocyte count in blood is strongly associated
with risk for coronary heart disease according to a previous
study.19
Our indirect evidence for an increase in systemic MPO
driven by tobacco smoking consists of data obtained from
the subjects who quit smoking (quitters) during the 6-year
observation period. In these subjects, we found a statisti-
cally significant negative correlation between the duration
of smoking cessation, on one hand, and change in blood MPO
on the other hand. Remarkably, we found correspondingly
strong negative correlations between the duration of
smoking cessation, on one hand, and change in blood
lysozyme and HNL, on the other hand. Thus, even though
our evidence for lysozyme and HNL remains weaker than
that for MPO, our findings are compatible with smoking
cessation being beneficial by limiting systemic inflamma-
tion; this is fully in line with the previously published
evidence of reduced numbers of inflammatory cells in blood
after smoking cessation, including the two potential sources
of MPO, neutrophils, and monocyte lineage cells.13,32,37
There are few previously published studies investigating
systemic inflammation during a substantial period of time in
tobacco smokers, with or without clinical symptoms of lung
disease. In one study, patients with chronic bronchitis
(presumably smokers) were compared with healthy control
subjects.38 Noteworthy, signs of systemic inflammation were
revealed in both groups, measured as blood concentration of
lactoferrin, lysozyme and MPO. Interestingly, lactoferrin was
increased more in patients with chronic bronchitis than in
control subjects 38; an observation that is compatible with
blood neutrophils being active in the development of lung
disease driven by tobacco smoking. In further support of an
active involvement of blood neutrophils, data from an
animal model of lung disease driven by tobacco smoking
indicate that exposure to tobacco smoke shortens the transit
time of neutrophils through the bone marrow.39 Moreover,
data from human subjects demonstrate that blood neutro-
phils from smokers display a morphologically less mature
phenotype than those from non-smokers. Of particular
interest, these immature blood neutrophils from smokers
express more MPO than do blood neutrophils from non-
smokers.40 Taken together, these findings forward the
possibility that tobacco smoking drives an increase in the
concentration of immature blood neutrophils capable of
releasing excess amounts of MPO. Tentatively, it is possible
that our current finding of increasing blood MPO in male
smokers relates to a similar mechanism.
We failed to demonstrate a meaningful and statistically
significant correlation between the measured inflammatory
markers in blood and the decline in lung function during the
6 years of observation. In hindsight, we have realised that
this may be due to the fact that our limited population of
‘‘clinically healthy’’ male subjects was highly selected; all
subjects had normal or close to normal lung function in spite
of long-lasting tobacco smoking. It seems likely that a far
greater variation in lung function (and presumably in
susceptibility to tobacco smoking), as well as a substantially
larger study population, would be needed to better
characterise the link between systemic inflammatory mar-
kers and impaired lung function.
In conclusion, our current study on male subjects provides
direct and indirect evidence that male smokers without
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inflammation, increasing within a 6-year period. Our study
forwards MPO primarily as a reproducible and early marker
of this systemic inflammation. These observations prompt
for a more extensive investigation of male and female
smokers in terms of the cellular origin of the increased MPO
and its value as an easily measurable and predicting factor
for future tobacco-induced lung disease such as chronic
bronchitis and COPD.
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